• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人局部复发性腹膜后肉瘤的治疗:来自跨大西洋澳大拉西亚腹膜后肉瘤工作组的最新共识方法。

Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.

机构信息

Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.

Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, and Department of Surgery, University of Toronto, Toronto, Canada.

出版信息

Ann Surg Oncol. 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29.

DOI:10.1245/s10434-022-11864-y
PMID:35767103
Abstract

BACKGROUND

Surgery is the mainstay of treatment for retroperitoneal sarcoma (RPS), but local recurrence is common. Biologic behavior and recurrence patterns differ significantly among histologic types of RPS, with implications for management. The Transatlantic Australasian RPS Working Group (TARPSWG) published a consensus approach to primary RPS, and to complement this, one for recurrent RPS in 2016. Since then, additional studies have been published, and collaborative discussion is ongoing to address the clinical challenges of local recurrence in RPS.

METHODS

An extensive literature search was performed, and the previous consensus statements for recurrent RPS were updated after review by TARPSWG members. The search included the most common RPS histologic types: liposarcoma, leiomyosarcoma, solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor.

RESULTS

Recurrent RPS management was evaluated from diagnosis to follow-up evaluation. For appropriately selected patients, resection is safe. Nomograms currently are available to help predict outcome after resection. These and other new findings have been combined with expert recommendations to provide 36 statements, each of which is attributed a level of evidence and grade of recommendation. In this updated document, more emphasis is placed on histologic type and clarification of the intent for surgical treatment, either curative or palliative. Overall, the fundamental tenet of optimal care for patients with recurrent RPS remains individualized treatment after multidisciplinary discussion by an experienced team with expertise in RPS.

CONCLUSIONS

Updated consensus recommendations are provided to help guide decision-making for treatment of locally recurrent RPS and better selection of patients who would potentially benefit from surgery.

摘要

背景

手术是治疗腹膜后肉瘤(RPS)的主要方法,但局部复发较为常见。不同组织学类型的 RPS 生物学行为和复发模式存在显著差异,这对治疗策略有重要影响。Transatlantic Australasian RPS Working Group(TARPSWG)发布了原发性 RPS 的共识方法,并于 2016 年为复发性 RPS 发布了补充共识。此后,发表了更多研究,且正在进行协作讨论以解决 RPS 局部复发的临床挑战。

方法

进行了广泛的文献检索,并在 TARPSWG 成员审查后更新了之前的复发性 RPS 共识声明。该搜索包括最常见的 RPS 组织学类型:脂肪肉瘤、平滑肌肉瘤、孤立性纤维瘤、未分化多形性肉瘤和恶性外周神经鞘瘤。

结果

从诊断到随访评估,对复发性 RPS 的管理进行了评估。对于适当选择的患者,切除是安全的。目前可提供列线图来帮助预测切除后的预后。这些和其他新发现与专家建议相结合,提供了 36 条陈述,每条陈述都有相应的证据水平和推荐等级。在本更新文件中,更强调了组织学类型,并澄清了手术治疗的意图,是治愈性还是姑息性。总体而言,为复发性 RPS 患者提供最佳护理的基本原则仍然是由具有 RPS 专业知识的经验丰富团队进行多学科讨论后,为患者制定个体化治疗方案。

结论

提供了更新的共识建议,以帮助指导局部复发性 RPS 的治疗决策,并更好地选择可能从手术中获益的患者。

相似文献

1
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.成人局部复发性腹膜后肉瘤的治疗:来自跨大西洋澳大拉西亚腹膜后肉瘤工作组的最新共识方法。
Ann Surg Oncol. 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29.
2
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.成人原发性腹膜后肉瘤(RPS)的治疗:来自跨大西洋澳大拉西亚 RPS 工作组的最新共识方法。
Ann Surg Oncol. 2021 Nov;28(12):7873-7888. doi: 10.1245/s10434-021-09654-z. Epub 2021 Apr 14.
3
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG).复发性腹膜后肉瘤切除术后的并发症:跨大西洋澳大利亚腹膜后肉瘤工作组(TARPSWG)的报告
Ann Surg Oncol. 2021 May;28(5):2705-2714. doi: 10.1245/s10434-020-09445-y. Epub 2021 Jan 2.
4
Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group.成人复发性腹膜后肉瘤(RPS)的管理:跨大西洋RPS工作组的共识方法。
Ann Surg Oncol. 2016 Oct;23(11):3531-3540. doi: 10.1245/s10434-016-5336-7. Epub 2016 Aug 1.
5
Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group.腹膜后肉瘤初次扩大切除术后复发后的结局:跨大西洋腹膜后肉瘤工作组的报告
Cancer. 2017 Jun 1;123(11):1971-1978. doi: 10.1002/cncr.30572. Epub 2017 Feb 2.
6
Surgical Management of Retroperitoneal Sarcoma.腹膜后肉瘤的外科治疗。
Curr Oncol. 2023 Apr 29;30(5):4618-4631. doi: 10.3390/curroncol30050349.
7
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.预测接受局部复发性腹膜后肉瘤切除术患者的生存:TARPSWG 的研究和新的列线图。
Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5.
8
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program.腹膜后肉瘤:跨大西洋澳大拉西亚腹膜后肉瘤工作组方案。
Curr Opin Oncol. 2021 Jul 1;33(4):301-308. doi: 10.1097/CCO.0000000000000746.
9
Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group.成人原发性腹膜后肉瘤(RPS)的管理:跨大西洋RPS工作组的共识方法。
Ann Surg Oncol. 2015 Jan;22(1):256-63. doi: 10.1245/s10434-014-3965-2. Epub 2014 Oct 15.
10
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).转移性腹膜后肉瘤的治疗:来自跨大西洋腹膜后肉瘤工作组(TARPSWG)的共识方法。
Ann Oncol. 2018 Apr 1;29(4):857-871. doi: 10.1093/annonc/mdy052.

引用本文的文献

1
Giant Intra-Abdominal Tumor, Compatible with Liposarcoma: A Case Report and Literature Review.巨大腹腔内肿瘤,符合脂肪肉瘤:病例报告及文献综述
Am J Case Rep. 2025 Sep 13;26:e948952. doi: 10.12659/AJCR.948952.
2
Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional Hyperthermia.区域热疗多模式治疗后,腹膜后软组织肉瘤手术是安全的。
Ann Surg Oncol. 2025 Aug 29. doi: 10.1245/s10434-025-18141-8.
3
Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review).

本文引用的文献

1
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms.腹膜后肉瘤幸存者的纵向预后:两个动态列线图的建立和外部验证。
Eur J Cancer. 2021 Nov;157:291-300. doi: 10.1016/j.ejca.2021.08.008. Epub 2021 Sep 20.
2
Disease Biology is "King" in Retroperitoneal Liposarcoma.疾病生物学在腹膜后脂肪肉瘤中占据“主导地位”。
Ann Surg Oncol. 2021 Dec;28(Suppl 3):832-834. doi: 10.1245/s10434-021-10472-6. Epub 2021 Aug 2.
3
Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
人类恶性肿瘤中的癌症相关成纤维细胞,尤其侧重于肉瘤(综述)
Int J Oncol. 2025 Oct;67(4). doi: 10.3892/ijo.2025.5785. Epub 2025 Aug 8.
4
The prognostic factors and treatment patterns of the first recurrence of retroperitoneal liposarcoma.腹膜后脂肪肉瘤首次复发的预后因素及治疗模式
Int J Clin Oncol. 2025 May 28. doi: 10.1007/s10147-025-02790-6.
5
Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.挑战与希望:脂肪肉瘤临床治疗与预后的最新研究趋势
Front Pharmacol. 2025 May 12;16:1529755. doi: 10.3389/fphar.2025.1529755. eCollection 2025.
6
Histology-driven tailoring of surgical approaches in retroperitoneal soft tissue sarcoma: retrospective cohort study.组织学驱动的腹膜后软组织肉瘤手术入路个体化:回顾性队列研究
BJS Open. 2025 May 7;9(3). doi: 10.1093/bjsopen/zraf050.
7
LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment.在接受新辅助治疗的软组织肉瘤患者中,乳酸脱氢酶(LDH)和血红蛋白作为预后因素比全身炎症指标表现更优。
BMC Cancer. 2025 Mar 18;25(1):496. doi: 10.1186/s12885-025-13889-4.
8
Bibliometric analysis of liposarcomas treatment from 2004 to 2023.2004年至2023年脂肪肉瘤治疗的文献计量分析。
J Cancer Res Clin Oncol. 2025 Jan 24;151(2):47. doi: 10.1007/s00432-025-06094-0.
9
Temporal variation in nutritional status and preoperative anemia among patients with retroperitoneal soft tissue sarcoma: a retrospective longitudinal cohort study.腹膜后软组织肉瘤患者营养状况及术前贫血的时间变化:一项回顾性纵向队列研究。
Langenbecks Arch Surg. 2025 Jan 22;410(1):48. doi: 10.1007/s00423-024-03585-5.
10
Integrated lipidomics and RNA-seq reveal prognostic biomarkers in well-differentiated and dedifferentiated retroperitoneal liposarcoma.综合脂质组学和RNA测序揭示高分化和去分化腹膜后脂肪肉瘤的预后生物标志物。
Cancer Cell Int. 2024 Dec 18;24(1):404. doi: 10.1186/s12935-024-03585-x.
经 Transatlantic Australasian Retroperitoneal Sarcoma Working Group(TARPSWG)分析,腹膜后脂肪肉瘤首次复发时的分化变化及结果。
Ann Surg Oncol. 2021 Nov;28(12):7854-7863. doi: 10.1245/s10434-021-10024-y. Epub 2021 Apr 27.
4
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program.腹膜后肉瘤:跨大西洋澳大拉西亚腹膜后肉瘤工作组方案。
Curr Opin Oncol. 2021 Jul 1;33(4):301-308. doi: 10.1097/CCO.0000000000000746.
5
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.在晚期去分化脂肪肉瘤患者中,selinexor 与健康相关的生活质量和疼痛。
Future Oncol. 2021 Aug;17(22):2923-2939. doi: 10.2217/fon-2021-0284. Epub 2021 Apr 15.
6
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.成人原发性腹膜后肉瘤(RPS)的治疗:来自跨大西洋澳大拉西亚 RPS 工作组的最新共识方法。
Ann Surg Oncol. 2021 Nov;28(12):7873-7888. doi: 10.1245/s10434-021-09654-z. Epub 2021 Apr 14.
7
Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review.根治性放疗在不可切除或残留腹膜后肉瘤治疗中的作用:机构队列分析和系统评价。
Cancer Control. 2021 Jan-Dec;28:1073274820983028. doi: 10.1177/1073274820983028.
8
Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma.基于 F-FDG PET/CT 最大标准摄取值(SUVmax)预测腹膜后脂肪肉瘤的组织学亚型和 FNCLCC 分级。
Contrast Media Mol Imaging. 2021 Jan 6;2021:7191363. doi: 10.1155/2021/7191363. eCollection 2021.
9
The role of F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study.F-FDG PET/CT 在腹膜后肉瘤中的作用——一项多中心回顾性研究。
J Surg Oncol. 2021 Mar;123(4):1081-1087. doi: 10.1002/jso.26379. Epub 2021 Jan 14.
10
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG).复发性腹膜后肉瘤切除术后的并发症:跨大西洋澳大利亚腹膜后肉瘤工作组(TARPSWG)的报告
Ann Surg Oncol. 2021 May;28(5):2705-2714. doi: 10.1245/s10434-020-09445-y. Epub 2021 Jan 2.